Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy

International Journal of Oncology

Volumn 49, Issue 2, 2016, Pages 471-478

  Park, Jae Hyun ^a   Jang, Miran ^a   Tarhan, Yunus Emre ^a   Katagiri, Toyomasa ^b   Sasa, Mitsunori ^c   Miyoshi, Yasuo ^d   Kalari, Krishna R ^e   Suman, Vera J ^e   Weinshilboum, Richard ^f   Wang, Liewei ^f   Boughey, Judy C ^g   Goetz, Matthew P ^f,h   Nakamura, Yusuke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Tokushima Breast Care Clinic   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e Knowledge and Evaluation Research Unit   (United States)

^f Molecular Pharmacology and Experimental Therapeutics   (United States)

^g Department of Surgery ^*  (United States)

^h MAYO CLINIC   (United States)

Author keywords

Biomarker; Breast cancer; T cell receptor; Tumor immunity; Tumor infiltrating T cell

Indexed keywords

CAPECITABINE; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER TISSUE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; NEOADJUVANT THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84978416083     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3540     Document Type: Article

References (34)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: 1687-1717, 2005.
3. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 24: 1940-1949, 2006.
4. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796-1804, 2012.
5. Printz C: I-SPY 2 may change how clinical trials are conducted: Researchers aim to accelerate approvals of cancer drugs. Cancer 119: 1925-1927, 2013.
6. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384: 164-172, 2014.
7. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113, 2010.
8. Jochems C and Schlom J: Tumor-infiltrating immune cells and prognosis: The potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236: 567-579, 2011.
9. Mao Y, Qu Q, Zhang Y, Liu J, Chen X and Shen K: The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. PLoS One 9: e115103, 2014.
10. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571, 2014.
11. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, Olshen RA, Weyand CM, Boyd SD and Goronzy JJ: Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci USA 111: 13139-13144, 2014.
12. Scaviner D and Lefranc MP: The human T cell receptor alpha variable (TRAV) genes. Exp Clin Immunogenet 17: 83-96, 2000.
13. Folch G and Lefranc MP: The human T cell receptor beta variable (TRBV) genes. Exp Clin Immunogenet 17: 42-54, 2000.
14. Clambey ET, Davenport B, Kappler JW, Marrack P and Homann D: Molecules in medicine mini review: The T cell receptor. J Mol Med Berl 92: 735-741, 2014.
15. Fang H, Yamaguchi R, Liu X, Daigo Y, Yew PY, Tanikawa C, Matsuda K, Imoto S, Miyano S and Nakamura Y: Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor and chains using next-generation sequencing (NGS). Oncoimmunology 3: e968467, 2015.
16. Liu X, Venkataraman G, Lin J, Kiyotani K, Smith S, Montoya M, Nakamura Y and Kline J: Highly clonal regulatory T-cell population in follicular lymphoma-inverse correlation with the diversity of CD8(+) T cells. Oncoimmunology 4: e1002728, 2015.
17. Jang M, Yew PY, Hasegawa K, Ikeda Y, Fujiwara K, Fleming GF, Nakamura Y and Park JH: Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunology 4: e1030561, 2015.
18. Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, et al: Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 50: 1227-1234, 2015.
19. Tamura K, Hazama S, Yamaguchi R, Imoto S, Takenouchi H, Inoue Y, et al: Characterization of T cell repertoire in tumor tissues and blood in advanced colorectal cancers through deep T cell receptor sequencing. Oncol Lett (In press).
20. Choudhury NJ, Kiyotani K, Yap KL, Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y and O'Donnell PH: Low T cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus: Oct 8, 2015. doi:10.1016/j.euf.2015.09.007.
21. Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, et al: Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 153: 435-443, 2015.
22. Giudicelli V, Chaume D and Lefranc MP: IMGT/GENE-DB: A comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 33: D256-D261, 2005.
23. Langmead B and Salzberg SL: Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357-359, 2012.
24. Bolotin DA, Shugay M, Mamedov IZ, Putintseva EV, Turchaninova MA, Zvyagin IV, Britanova OV and Chudakov DM: MiTCR: Software for T-cell receptor sequencing data analysis. Nat Methods 10: 813-814, 2013.
25. Turley SJ, Cremasco V and Astarita JL: Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15: 669-682, 2015.
26. Park JH: Immune microenvironment to predict response of cancer chemotherapy and radiotherapy. In: Immunopharmacogenomics. Nakamura Y (ed). Springer, Tokyo, pp143-155, 2015.
27. Gebremeskel S and Johnston B: Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on clinical studies and considerations for combined therapies. Oncotarget 6: 41600-41619, 2015.
28. Hong M, Puaux A-L, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prévost-Blondel A, Avril MF, Nardin A, et al: Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71: 6997-7009, 2011.
29. Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ and Noguchi S: Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 136: 107-116, 2012.
30. Matsushita N, Pilon-Thomas SA, Martin LM and Riker AI: Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 333: 167-179, 2008.
31. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P and Ghiringhelli F: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14: 2413-2420, 2008.
32. Han A, Glanville J, Hansmann L and Davis MM: Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol 32: 684-692, 2014.
33. Nakamura Y: Challenges and future directions of immunopharmacogenomics. In: Immunopharmacogenomics. Nakamura Y (ed). Springer, Tokyo, pp159-162, 2015.
34. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al: NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21: 914-921, 2015.